Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) CFO Jack Anders sold 2,635 shares of the company's stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $45.40, for a total transaction of $119,629.00. Following the completion of the sale, the chief financial officer now directly owns 96,470 shares of the company's stock, valued at $4,379,738. This represents a 2.66 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.
Jack Anders also recently made the following trade(s):
- On Friday, October 11th, Jack Anders sold 10,000 shares of Revolution Medicines stock. The shares were sold at an average price of $50.30, for a total value of $503,000.00.
Revolution Medicines Price Performance
RVMD opened at $42.97 on Thursday. Revolution Medicines, Inc. has a 12 month low of $25.60 and a 12 month high of $62.40. The business has a 50-day moving average of $52.10 and a two-hundred day moving average of $46.03. The stock has a market capitalization of $7.23 billion, a price-to-earnings ratio of -11.97 and a beta of 1.40.
Is Starlink Set For The Largest IPO In History?
From Paradigm Press | Ad
He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant.
Then, he did it again with Tesla… which is up more than 19,500% since 2010.
For perspective, that turns $100 invested into almost $20,000!
Click here now for the urgent details.
Revolution Medicines (NASDAQ:RVMD - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.05). During the same quarter in the prior year, the firm earned ($0.99) earnings per share. Equities research analysts anticipate that Revolution Medicines, Inc. will post -3.5 earnings per share for the current year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the company. Lord Abbett & CO. LLC acquired a new stake in shares of Revolution Medicines in the 3rd quarter worth approximately $83,082,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Revolution Medicines during the 3rd quarter worth $801,000. Geode Capital Management LLC raised its position in shares of Revolution Medicines by 8.7% during the third quarter. Geode Capital Management LLC now owns 3,627,025 shares of the company's stock worth $164,517,000 after purchasing an additional 291,369 shares during the period. Barclays PLC boosted its position in shares of Revolution Medicines by 187.1% in the 3rd quarter. Barclays PLC now owns 294,664 shares of the company's stock valued at $13,362,000 after purchasing an additional 192,021 shares during the period. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of Revolution Medicines in the third quarter worth about $247,000. Institutional investors own 94.34% of the company's stock.
Wall Street Analyst Weigh In
A number of research analysts recently issued reports on the company. Oppenheimer lifted their target price on Revolution Medicines from $55.00 to $60.00 and gave the company an "outperform" rating in a report on Monday, October 28th. Piper Sandler lifted their price target on shares of Revolution Medicines from $57.00 to $70.00 and gave the stock an "overweight" rating in a research note on Thursday, November 7th. Wedbush reiterated an "outperform" rating and set a $70.00 target price on shares of Revolution Medicines in a research note on Monday, December 2nd. JPMorgan Chase & Co. raised their price objective on shares of Revolution Medicines from $63.00 to $71.00 and gave the stock an "overweight" rating in a report on Tuesday, December 3rd. Finally, HC Wainwright increased their target price on shares of Revolution Medicines from $64.00 to $72.00 and gave the company a "buy" rating in a research report on Wednesday, December 4th. Eleven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Revolution Medicines has a consensus rating of "Buy" and an average target price of $63.67.
Read Our Latest Research Report on Revolution Medicines
About Revolution Medicines
(
Get Free Report)
Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
